This company has been marked as potentially delisted and may not be actively trading. Aeglea BioTherapeutics (AGLE) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock AGLE Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Spyre Therapeutics Advances IBD Treatment PipelineNovember 9, 2024 | markets.businessinsider.comNorthwest Biotherapeutics Stock (OTC:NWBO), Analyst Ratings, Price Targets, PredictionsFebruary 21, 2024 | benzinga.comBridge Biotherapeutics Inc.January 30, 2024 | wsj.comSpyre Therapeutics Announces $180 Million Private PlacementDecember 7, 2023 | finance.yahoo.comAeglea Biotherapeutics announces name change to Spyre TherapeuticsNovember 27, 2023 | msn.comAeglea BioTherapeutics Changes Name To Spyre Therapeutics; To Begin Trading Under Symbol SYRENovember 27, 2023 | markets.businessinsider.comAeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBDNovember 27, 2023 | finance.yahoo.comAeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 9, 2023 | finance.yahoo.comAeglea BioTherapeutics to Participate in Upcoming November Investor ConferencesOctober 30, 2023 | finance.yahoo.comAeglea BioTherapeutics (AGLE) Price Target Increased by 2435.71% to 18.11October 5, 2023 | msn.comAeglea BioTherapeutics Announces Grants of Inducement AwardsOctober 2, 2023 | finance.yahoo.comAeglea BioTherapeutics to Participate in Upcoming September ConferenceSeptember 14, 2023 | finance.yahoo.comAeglea Biotherapeutics (AGLE) Gets a Buy from Stifel NicolausSeptember 14, 2023 | markets.businessinsider.comAeglea BioTherapeutics (NASDAQ:AGLE) Cut to Sell at StockNews.comSeptember 8, 2023 | marketbeat.comAeglea BioTherapeutics, Inc.: Aeglea BioTherapeutics Announces Reverse Stock SplitSeptember 8, 2023 | finanznachrichten.deAeglea BioTherapeutics (Nasdaq:AGLE) HeadlineTrading was temporarily halted for "AGLE" at 09:09 AM with a stated reason of "LULD pause."...September 8, 2023 | marketbeat.comAeglea BioTherapeutics Announces Reverse Stock SplitSeptember 7, 2023 | finance.yahoo.comAeglea BioTherapeutics appoints Burrows as CFO, King-Jones as CLOSeptember 5, 2023 | seekingalpha.comAeglea BioTherapeutics Appoints Scott Burrows As Chief Financial OfficerSeptember 5, 2023 | markets.businessinsider.comAeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-JonesSeptember 5, 2023 | finance.yahoo.comWells Fargo Maintains Aeglea BioTherapeutics (AGLE) Equal-Weight RecommendationAugust 16, 2023 | msn.comAeglea BioTherapeutics, Inc.: Aeglea BioTherapeutics Reports Second Quarter 2023 Financial ResultsAugust 11, 2023 | finanznachrichten.deAeglea BioTherapeutics Reports Second Quarter 2023 Financial ResultsAugust 11, 2023 | finance.yahoo.comAeglea BioTherapeutics (NASDAQ: AGLE)August 10, 2023 | fool.comAeglea BioTherapeutics (AGLE) Price Target Decreased by 54.54% to 1.45August 3, 2023 | msn.comAeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica PharmaJuly 27, 2023 | finance.yahoo.comAeglea initiated with Buy at Stifel citing potential in IBD spaceJuly 25, 2023 | seekingalpha.comStifel Initiates Coverage of Aeglea BioTherapeutics (AGLE) with Buy RecommendationJuly 25, 2023 | msn.comAeglea Biotherapeutics (AGLE) Initiated with a Buy at Stifel NicolausJuly 25, 2023 | markets.businessinsider.comFunding wrap: Former Dell Med dean raises $30MJune 26, 2023 | bizjournals.comAeglea BioTherapeutics Announces Grant of Inducement AwardsJune 23, 2023 | finance.yahoo.comM&A Wrap: Aeglea grabs another biotech co., $210M; Wealth manager acquiredJune 23, 2023 | bizjournals.comAeglea BioTherapeutics stock skyrockets as it boosts inflammatory bowel disease portfolio with Spyre Therapeutics acquisitionJune 22, 2023 | proactiveinvestors.comWhy Is Aeglea BioTherapeutics (AGLE) Stock Up 392% Today?June 22, 2023 | investorplace.comAeglea BioTherapeutics Shares Spike After Merger, New FundingJune 22, 2023 | marketwatch.comAeglea BioTherapeutics Stock Surges Over 400% Today - What's Going OnJune 22, 2023 | benzinga.comAeglea BioTherapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS LagsMay 13, 2023 | finance.yahoo.comRecap: Aeglea BioTherapeutics Q1 EarningsMay 12, 2023 | msn.com10-Q: AEGLEA BIOTHERAPEUTICS, INC.May 12, 2023 | marketwatch.comAeglea Biotherapeutics (AGLE) Reports Q1 Loss, Tops Revenue EstimatesMay 11, 2023 | finance.yahoo.comAeglea BioTherapeutics, Inc.: Aeglea BioTherapeutics Reports First Quarter 2023 Financial ResultsMay 11, 2023 | finanznachrichten.deAeglea BioTherapeutics Reports First Quarter 2023 Financial ResultsMay 11, 2023 | finance.yahoo.comLifeSci Capital Downgrades Aeglea BioTherapeutics (AGLE)April 13, 2023 | msn.comJonesTrading Downgrades Aeglea BioTherapeutics (AGLE)April 13, 2023 | msn.comAeglea (AGLE) Plunges 26% After Rare Disorder Drug Study FailsApril 13, 2023 | msn.comWhy Are Aeglea BioTherapeutics Shares Sinking Today?April 12, 2023 | msn.comJonesTrading Sticks to Its Hold Rating for Aeglea Biotherapeutics (AGLE)April 12, 2023 | markets.businessinsider.comAeglea slumps ~25% as trial results trigger strategic options, workforce reductionApril 12, 2023 | msn.comAeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to Explore Strategic AlternativesApril 12, 2023 | finance.yahoo.comAeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 17, 2023 | finance.yahoo.com Get Aeglea BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AGLE and its competitors with MarketBeat's FREE daily newsletter. Email Address AGLE Media Mentions By Week AGLE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AGLE News Sentiment▼0.000.99▲Average Medical News Sentiment AGLE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AGLE Articles This Week▼00▲AGLE Articles Average Week Get Aeglea BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AGLE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CYBN News Today PROC News Today OPTN News Today VIRI News Today PYRGF News Today AADI News Today OSTX News Today ATNM News Today EGRX News Today ELYM News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AGLE) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aeglea BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aeglea BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
